Kornimate/medical-research-clean huggingface dataset:
to evaluate the safety of treating rheumatologic and metabolic patients with molecular hydrogen supplement.

Conditions: Autoimmune Diseases; Metabolic Disease

Summary: the latest international research shows that supplementation of hydrogen molecules as an aid, adjuvant, can speed up the course of the disease. the purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in different dose exposures for a clinical study in rheumatologic and metabolic patients. patients will receive a different dosage of hydrogen capsules with their conventional treatment for a month. investigators will test for any changes in haematologic, urine analysis and health status during and following the exposure period.

according to the current literature, there is a lack of specific drugs for chronic inflammatory symptoms which develop from many refractory diseases with complicated clinical features. hydrogen supplement has been shown to have significant removal effects on free radicals and reduce chronic inflammation. with these benefits, molecular hydrogen may have the ability to speed up the recovering the disease. the purpose of this study is to determine the safety and possible efficacy of hydrogen supplements in the different doses of hydrogen capsules for a clinical study in rheumatologic and metabolic patients. study design: 15 rheumatologic patients and 15 metabolic patients will be recruited from the min-sheng general hospital for this study. participants will be screened by doctors for their eligibility and undergo a series of tests (questionnaires and examinations). consenting participants will then be allocated into 3 groups by different dosage (low, n=5; medium, n=5; high, n=5). participants will receive 1 (low), 3 (medium) or 6 (high) capsules every day for one month. participants will be examined their regular haematology, urine and health status before and after the intervention.

Eligibility criteria:
inclusion criteria: * age 20 to 70 with autoimmune or metabolic diseases * able to compliant with the protocol * able to return to the hospital regularly exclusion criteria: * pregnancy * expected pregnancy
accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation

Conditions: Breast Cancer

Summary: the aim of this phase 3 randomised trial is to compare the efficacy and safety of whole breast radiotherapy to accelerated partial breast irradiation using intensity-modulated radiotherapy technique in selected early breast cancer patients after breast conserving surgery.

the surgeons were requested to place clips at the borders of the surgical bed, using a minimum of four clips. the presence of surgical clips was a selection criterion to avoid geographic misses. computed tomography (ct) scanning was performed using 0.3-cm thick-slices and a slice spacing of 0.3 cm. in patients assigned to apbi arm, the clinical target volume (ctv) was drawn with a uniform 1-cm three-dimensional margin around the surgical clips. the ctv was limited to 3 mm from the skin surface and 3 mm from the lung-chest wall interface. a second uniform, three-dimensional 1-cm margin was added to the ctv to obtain the planning target volume (ptv). the ptv was allowed to extend 4 mm inside the ipsilateral lung and was limited to 3 mm from the skin. the ipsilateral and contralateral breast, ipsilateral and contralateral lung, heart, and spinal cord were contoured as organs at risk. all the regions of interest were contoured according to the international commission on radiation units and measurements reports 50 and 62 recommendations. no respiratory control was used. concerning the experimental arm (accelerated partial breast irradiation), a dose of 30 gy in five fractions at 6 gy/fraction was prescribed. the following constraints were adopted for plan optimization: ptv coverage: 100% of ptv covered by 95% of the prescribed dose (v28.5 = 100%); maximal dose to ptv \ 50% covered by a dose of \>50% of the prescribed dose (v15 \ 20% covered by a dose \>10 gy (v10\ 10% covered by a dose \>5 gy (v5\ 10% covered by a dose \>3 gy (v3 \<10%).

Eligibility criteria:
inclusion criteria: * age at presentation \>40 y * tumor size \<25 mm * wide excision or quadrantectomy with clear margins (\>5 mm) * clips placed in tumor bed * full informed consent from patient exclusion criteria: * cardiac dysfunction * forced expiratory volume in 1 second (fev1) \<1 l/m * extensive intraductal carcinoma * multifocal cancer * psychiatric problems * recurrent breast cancer

Keywords: breast cancer early breast cancer adjuvant breast cancer accelerated partial breast irradiation intensity modulated radiotherapy
sugars-sweetened beverages and exercise on glycaemic response and subjective appetite in children

Conditions: Glycemic Control; Subjective Appetite

Summary: the purpose of the study is to understand the role chocolate milk compared to a fruit drink, with and without exercise, on glycaemic regulation and subjective appetite in children. the investigators hypothesize that chocolate milk in combination with exercise will have the greatest effect attenuating glycaemic response. blood glucose will be measured by finger prick following drink consumption (0 min) and exercise or sitting (15 min), and at 65 minutes. subjective appetite will be measured at 0, 20, 35, 50 and 65 minutes.


Eligibility criteria:
inclusion criteria: * healthy, boy, born at full term and normal birth weight exclusion criteria: * girls, have significant learning, behavioral, or emotional difficulties
contribution of hypnosis to anxiety and pain in brachytherapy patients

Conditions: Cancer; Brachytherapy

Summary: formal hypnosis is a non-drug technique known to decrease anxiety and pain during the preoperative procedure. in brachytherapy, the practice of hypnosis has been shown to be feasible and beneficial for patients treated for prostate cancer the goal of the study is to demonstrate the added value of hypnosis during a brachytherapy detachment by improving the comfort of the patient. the investigators want to evaluate the contribution of hypnosis during brachytherapy detachment by quantifying the anxiety and pain felt by the patient during the procedure.


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 and ≤ 80 years * patients expected to benefit a brachytherapy detachment under kalinox® for one of the types of applications described below: * deep interstitial application: anal canal, vagina, vulva * gynecological application: mold, utrecht® system or venezia® system * ability to provide written informed consent * patients affiliated to the social security system exclusion criteria: * minor and patients over 80 years old * patients with major hearing loss * patients who had recent ocular surgery with oculiare gas injection. * patients suffering from psychotic disorders, and dementias. * patients who do not understand the french language * patients under guardianship or deprived of liberty * patients with a contraindication to the administration of kalinox®

Keywords: cancer hypnosis care management
the effect of a shoulder training program to prevent shoulder pain among girls in junior team handball

Conditions: Shoulder Pain

Summary: very little is known about the potential for preventing the prevalence of shoulder complaints in handball players, particularly younger players. the aim of this study is to evaluate the effect of a shoulder training program on shoulder pain during a season of team handball.

six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition seasons. three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training. effects of this strength--training program were evaluated by comparing pre-- and post--training data from a survey on shoulder complaints based on a self--report questionnaire (quick dash) and visual analogue scale (vas). the players completed the vas on pain once a month. in addition to that the players were tested in a maximum push up test, dynamometer test for internal and external rotation strength in the shoulder and throwing distance in the pre- and posttest.

Eligibility criteria:
inclusion criteria: - team handball players in the top division in the j16 class in the trøndelag region in norway exclusion criteria: - previous shoulder operations og fractures in the shoulder region

Keywords: exercise movement techniques
apple women's health study

Conditions: Menstrual Cycle; Ovulation; Menstruation; Polycystic Ovary Syndrome; Infertility; Menopause; Reproduction; Reproductive Health

Summary: this is an observational longitudinal study to advance the understanding of menstrual cycle and gynecologic health conditions including pcos, infertility and breast cancer.the study will be hosted within the research app(available on app store), which allows a user to find, enroll, and participate in apple-supported health-related research studies.


Eligibility criteria:
inclusion criteria: * have menstruated at least once * be at least 18 years old (at least 19 years old in alabama and nebraska, at least 21 years old in puerto rico) * live in the united states of america * be comfortable communicating in written and spoken english * have installed the apple research app on your iphone * not share your icloud account or iphone with anyone else * be willing and able to provide informed consent to participate in the study

Keywords: menstruation menstrual cycle ovulation polycystic ovary syndrome infertility menopause reproduction reproductive health
a study to investigate the pharmacokinetics of ro7223280 in critically ill participants with bacterial infections

Conditions: Bacterial Infections

Summary: the main aim of the study is to investigate the plasma pharmacokinetics (pk) and safety of intravenous (iv) administration of a single dose of 400 milligrams (mg) or 600 mg ro7223280 in critically ill participants with bacterial infections.


Eligibility criteria:
inclusion criteria: * illness requiring treatment in an intensive care unit (icu) at the time of enrolment * ongoing clinical syndrome meeting at least one of the following criteria: 1. habp: bacterial pneumonia diagnosed after more than 48 hours of hospitalization or within 7 days after a hospital discharge 2. ventilator-associated bacterial pneumonia (vabp): bacterial pneumonia diagnosed after more than 48 hours of mechanical ventilation or within 72 hours after weaning 3. bacteremia confirmed by the presence of a bacterial pathogen in a blood culture drawn within 7 days prior to dosing and with the defined focus of infection. 4. for cohort 4 only: mechanically ventilated participants who have a bal procedure planned as part of routine practice for a day that can function as day 1. exclusion criteria: * ongoing documented catheter-related bacteraemia as the sole ongoing infection * major surgery within 48 hours prior to dosing or major surgery expected within 48 hours after the start of the infusion * known chronic severe hepatic impairment (child-pugh class c). note: acute severe hepatic impairment is not exclusionary
crystalloids for aki in shock patients

Conditions: Shock

Summary: fluid resuscitation is important in shock therapy, but the choice of fluids, especially the choice of crystalloid is under debate. it is said that normal saline is related to hyperchloremia， which might lead to acute kidney injury. thus the hypothesis of the study is to explicit whether balanced salt solution could reduce the incidence of acute kidney injury when compared with normal saline.


Eligibility criteria:
inclusion criteria: * shock patients exclusion criteria: * history of chronic renal failure

Keywords: shock crystalloid acute kidney injury
pharmacology of adjuvant hormonotherapy in breast cancer

Conditions: Hormono-depending Adjuvant Breast Cancer

Summary: this is a biomedical study of interventional type, multicenter, inter-regional. patients with hormono-depending breast cancer, for which an indication of adjuvant hormonotherapy treatment (according to the current treatments) was retained, will be enrolled in this study. the main objective is to estimate the correlations between pharmacokinetic and pharmacogenetic parameters of adjuvant hormonal breast cancer treatment, during the first 3 years.


Eligibility criteria:
inclusion criteria: 1. patient of more than 18 years old (menopaused or not) 2. invasive breast cancer non-metastatic locally controlled by surgery with or without radiotherapy. previous treatment with chemotherapy is allowed including trastuzumab 3. cancer hormone-expressing er and / or pr (\> 10% tumor cells in technical hic) 4. having a staging exploring bone, liver, lung and showing no abnormality secondary (for sub-centimeter tumors, the staging is not necessary) 5. who \<2 6. before the initiation of adjuvant hormonal therapy (tamoxifen, anastrozole, letrozole or exemestane) and whatever the approach chosen by the investigator (5 years of tamoxifen, 5 years of anti-aromatase or sequential patterns) 7. signed consent collected before any specific procedure in the study 8. patient member in a national insurance scheme. exclusion criteria: 1. patient previously treated for breast cancer receiving hormonal therapy with tamoxifen, anastrozole, letrozole or exemestane regardless of the scheme 2. metastatic breast cancer 3. history of another cancer diagnosed within 5 years before or uncontrolled except carcinoma in situ of cervix carcinoma, nonmelanoma skin, breast cancer (in this case, treatment with hormone therapy should be stopped for at least 6 months) 4. any other medical or psychiatric condition or laboratory abnormality severe acute or chronic making the inclusion of the patient in the study inappropriate in the opinion of the investigator 5. patient unable to follow procedures, visits, examinations described in the study 6. pregnant women or nursing mothers can not participate in the study 7. women of childbearing age must use effective contraception at study entry and up to at least three months after the end of treatment 8. patient under legal guardianship

Keywords: pharmacokinetics pharmacogenetic tamoxifen anti-aromatases breast cancer pharmacodynamy observance
augmentation of maxillary horizontal and vertical bone deficiency using mineralized plasmatic matrix

Conditions: Alveolar Ridge Abnormality of Maxilla

Summary: a new technique of grafting introduce called mineralized plasmatic matrix. this technique can be used in grafting in anterior zone giving a good results and bone substitution occur using allograft or xenograft. the bone graft have a good consistency when it mixed with plasma give easy application, strength and stability of the graft. also plasma rich with cgf (cellular growth factors).

patients suffering from anterior maxillary vertical and horizontal bone loss will be treated using a xeno-graft mixed with the same patient plasma that extracted from his own blood during the operation this graft will be stabilized by collagen membrane and surgical tags. patients will be follow up for 6 months to measure amount of bone loss of the xeno-graft during this period post operative using c.b.c.t

Eligibility criteria:
inclusion criteria: * age: from 20 to 40 years old * no history of previous grafting. * no history of previous implant placement * medically free e.g no debilitating diseases exclusion criteria: * smoker patients. * alcoholic patients * pregnant. * drug abusers. * hypertensive , diabetic, having problems or disease in kidney and/or liver. * thyroid disease. * problem in vit.d absorption or in calcitonin hormone secretion. * history of blood transfusion or donating blood less than 4 months. * patient under corticosteroid therapy. * neurologicaly unstable patients. * history of radiotherapy or chemo-therapy. * patient undergo spect c.t scan less than 4 months .

Keywords: mineralized plasmatic matrix sticky bone plasma autogeous fibrin glue
brain stimulation and rehabilitation for adults with chronic, severe arm motor impairment after stroke

Conditions: Stroke; Hemiplegia; Hemiparesis

Summary: this pilot study will examine a combination therapy for adults with chronic, severe motor impairment of an arm after stroke. the intervention will combine brain stimulation with physical rehabilitation of the arm on the side of the body more-affected by stroke.

the overarching goal of this program of research is to develop a therapy that produces meaningful and persistent improvements in function of the more-affected arm in stroke survivors with severe, chronic hemiparesis. no treatment with an established evidence base is available now for this large group, who have barely perceptible voluntary movement of the more-affected fingers and wrist. the lab of e. taub and g. uswatte has developed an expanded version of constraint-induced movement therapy (cimt) for this population that has evidence of efficacy for improving use in daily life of the more-affected arm from a case series and small randomized controlled trial (rct). the original version of cimt is a form of physical rehabilitation that has evidence of efficacy from multiple rcts for improving use in daily life of the more-affected arm in adults with mild to moderate hemiparesis after stroke. cimt has also been shown to produce neuroplastic changes in both grey and white matter structures. expanded cimt (ecimt) combines cimt with neurodevelopmental techniques (ndt) for managing tone. studies from by j. szaflarski and by others suggest that priming cns tissue for training by electrically stimulating the brain regions that control the target function with excitatory intermittent theta burst stimulation (itbs) augments the benefits of neurorehabilitation. this pilot study will evaluate the feasibility of combining ecimt with brain stimulation by itbs and, on a preliminary basis, will evaluate whether this combination therapy boosts treatment outcomes relative to ecimt alone.

Eligibility criteria:
inclusion criteria: * stroke * \> 12 months after stroke onset * severe hemiparesis of more-affected arm exclusion criteria: * substantial use of the more-affected arm in daily life * frailty or insufficient stamina to carry out the requirements of the therapy * other neurological or musculoskeletal problems, including pain, affecting the more-affected arm * severe cognitive deficits

Keywords: stroke hemiplegia hemiparesis arm upper-extremity motor impairment transcranial magnetic stimulation (tms) brain stimulation neuroplasticity
neuroimaging correlates of memory decline following carotid interventions

Conditions: Carotid Artery Stenosis

Summary: carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. characterizing risk factors for cognitive decline following carotid interventions and individualizing treatment strategy based on those risks can minimize procedure-associated cognitive dysfunction. neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. in this protocol, we hope to determine how cerebral blood flow and baseline white matter abnormality in the vulnerable region modify the frequency and cognitive effect of microembolization following carotid revascularization procedures.


Eligibility criteria:
inclusion criteria: * patient is male or female \>40 yrs of age. * patient has occlusive extracranial carotid stenosis (≥70%) * patient is scheduled to undergo a carotid revascularization procedure * patient agrees to voluntarily participate in the study and signs an informed consent. * patient agrees to be available for follow-up and is able to participate in all study testing procedures. * patient has sufficient visual and auditory acuity for cognitive testing. exclusion criteria: * patient is unable to safely and comfortably undergo mr imaging procedures (e.g., claustrophobia, implanted medical devices that are mri incompatible such as pacemaker, defibrillator, neural stimulator etc) * patient has an untreated or unsuccessfully controlled psychiatric disease (schizophrenia, bipolar disorder). * patient has prominent suicidal or homicidal ideation. * patient has acute illness or unstable chronic illness (e.g. uncontrolled hypertension, hepatic encephalopathy, portal hypertension, ascites, and esophageal varices, pancreatitis). * patient with a history of neurological (e.g., multiple sclerosis, seizure disorder, parkinson's disease) or systemic illness affecting central nervous system function. * patient has prior closed head injury with ≥24 hours of amnesia.

Keywords: carotid artery stenting carotid endarterectomy magnetic resonance imaging (mri) neuropsychological testing microemboli
toric intraocular lens implantation in pediatric cataract

Conditions: Cataract Congenital; Astigmatism; IOL

Summary: to evaluate the visual and refractive outcomes after an intraocular lens (iol) implantation in pediatric eyes with cataract and preexisting corneal astigmatism

this single-center, single-blinded, prospective, randomized controlled trial was performed at two sites of kazakh eye research institute. children with pediatric cataract and corneal astigmatism were included and randomized to two groups for pediatric cataract surgery with toric and non-toric intraocular lens (iol) implantation. the uncorrected and corrected distance visual acuity, near visual acuity, keratometry data, and residual astigmatism were evaluated. the purpose of this study is to evaluate the visual and refractive outcomes after a toric iol implantation in pediatric eyes with cataract and preexisting corneal astigmatism.

Eligibility criteria:
inclusion criteria: 1. visually significant cataract; 2. corneal astigmatism more than 1.25 diopters; 3. children aged ≥ 6 years and \< 18 years. exclusion criteria: 1. patients with a corneal diameter less than 9 mm; 2. presence of corneal scarring; 3. irregular astigmatism; 4. intraocular pressure more than 25 mm hg; 5. active inflammatory process of the eyeball or signs of a previous episode of inflammation; 6. traumatic, subluxated, or complicated cataract; 7. persistent fetal vasculature; 8. diseases of the optic nerve or macula that may limit visual potential; 9. history of previous intraocular surgeries; 10. performing posterior capsulorhexis intraoperatively.

Keywords: cataract congenital astigmatism toric iol
methylnaltrexone for treatment of opiate-induced constipation in the intensive care unit

Conditions: Opioid-induced Constipation

Summary: the purpose of this study is to determine if there will be a significantly higher incidence of a bowel movement with methylnaltrexone vs. placebo within 4 hours +- 45 minutes with decreased need for rescue medications in the intensive care unit in patients with opioid-induced constipation. patients will also be managed with an aggressive bowel management protocol.


Eligibility criteria:
inclusion criteria: * 18 years of age or older in the icu * opioids for analgesia for at least 24 hours. * opioid-induced constipation with no bowel movement within the last 72 hours. * women of childbearing potential had negative pregnancy tests. exclusion criteria: * contraindication to use of the gi tract * diarrhea on admission * bowel surgery within 8 weeks of admission * ileostomy or colostomy * not expected to live or stay more than 3 days in the intensive care unit * constipation that was not primarily caused by opioids (as determined by the investigator) * no opioid use in the last 24 hours, * mechanical gastrointestinal obstruction * an indwelling peritoneal catheter * clinically active diverticular disease * fecal impaction * acute surgical abdomen * history of crohn's disease or ulcerative colitis * on palliative care * less than 18 years old * bowel movement in last 72 hours.

Keywords: intensive care unit constipation bowel management